IRIS

ASCIERTO, PAOLO ANTONIO

ASCIERTO, PAOLO ANTONIO  

DIPARTIMENTO DI NEUROSCIENZE E SCIENZE RIPRODUTTIVE ED ODONTOSTOMATOLOGICHE  

Mostra records
Risultati 1 - 20 di 656 (tempo di esecuzione: 0.026 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Molecular Pathogenesis of Melanoma: Established and Novel Pathways 2.1 Contributo in volume (Capitolo o Saggio) 2012 Ascierto, P; Ascierto, Ml; Capone, M; Elaba, Z; Murphy, Mj; And Palmieri, G
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study 1.1 Articolo in rivista 2014 Larkin, J; Del Vecchio, M; Ascierto, P; Krajsova, I; Schachter, J; Neyns, B; Espinosa, E; Garbe, C; Sileni, Vc; Gogas, H; Miller, Wh; Mandala, M; Hospers, Gap; Arance, A; Queirolo, P; Hauschild, A; Brown, Mp; Mitchell, L; Veronese, L; Blank, Cu
Prognostic value of CD40 in adult soft tissue sarcomas 1.1 Articolo in rivista 2004 Ottaiano, A; De Chiara, A; Perrone, F; Botti, G; Fazioli, F; De Rosa, V; Mozzillo, N; Ravo, V; Morrica, B; Gallo, C; Pisano, C; Napolitano, M; Ascierto, P; Laffaioli, Rv; Apice, G
CD40 activation as potential tool in malignant neoplasms 1.1 Articolo in rivista 2002 Ottaiano, A; Pisano, C; De Chiara, A; Ascierto, P; Botti, G; Barletta, E; Apice, G; Gridelli, C; Iaffaioli, Vr
Expanded access programmes: patient interests versus clinical trial integrity 1.1 Articolo in rivista 2015 Ascierto, P
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 1.1 Articolo in rivista 2012 Di Giacomo, Am; Ascierto, P; Pilla, L; Santinami, M; Ferrucci, Pf; Giannarelli, D; Marasco, A; Rivoltini, L; Simeone, E; Nicoletti, Svl; Fonsatti, E; Annesi, D; Queirolo, P; Testori, A; Ridolfi, R; Parmiani, G; Maio, M
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial 1.1 Articolo in rivista 2020 Gutzmer, R; Stroyakovskiy, D; Gogas, H; Robert, C; Lewis, K; Protsenko, S; Pereira, Rp; Eigentler, T; Rutkowski, P; Demidov, L; Manikhas, Gm; Yan, Yb; Huang, Kc; Uyei, A; Mcnally, V; Mcarthur, Ga; Ascierto, P
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group 1.1 Articolo in rivista 2003 Ascierto, P
Computer-aided diagnosis of melanocytic lesions 1.1 Articolo in rivista 2005 Ascierto, P
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study 1.1 Articolo in rivista 2017 Ascierto, P
Soluble interleukin-2 receptor in stage I-III melanoma 1.1 Articolo in rivista 2006 Ascierto, P
Emerging therapeutics for melanoma 2.1 Contributo in volume (Capitolo o Saggio) 2012 Francesco, M Marincola; Ascierto, P; John, M Kirkwood
Adjuvant Therapy in Resected Melanoma REPLY 1.1 Articolo in rivista 2018 Weber, J; Qureshi, A; Ascierto, P
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 1.1 Articolo in rivista 2008 Ascierto, P
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 1.1 Articolo in rivista 2014 Larkin, J; Ascierto, P; Dreno, B; Atkinson, V; Liszkay, G; Maio, M; Mandala, M; Demidov, L; Stroyakovskiy, D; Thomas, L; de la Cruz-Merino, L; Dutriaux, C; Garbe, C; Sovak, Ma; Chang, I; Choong, N; Hack, Sp; Mcarthur, Ga; Ribas, A
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 1.1 Articolo in rivista 2013 Ascierto, P
Prognostic value of serum VEGF in melanoma patients: a pilot study 1.1 Articolo in rivista 2004 Ascierto, P
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 1.1 Articolo in rivista 2013 Ascierto, P; Minor, D; Ribas, A; Lebbe, C; O'Hagan, A; Arya, N; Guckert, M; Schadendorf, D; Kefford, Rf; Grob, Jj; Hamid, O; Amaravadi, R; Simeone, E; Wilhelm, T; Kim, Kb; Long, Gv; Martin, Am; Mazumdar, J; Goodman, Vl; Trefzer, U
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 1.1 Articolo in rivista 2013 Ascierto, P
The role of BRAF V600 mutation in melanoma 1.1 Articolo in rivista 2012 Ascierto, P